뉴스

T.N. government announces zero-tolerance approach towards delays in sanctioning building plan approvals

State warns planning officials of disciplinary action for negligence and violation of transparency processes

Odisha government clears key road for Vedanta’s mining project

State government approves road construction in favour of State-run Odisha Industrial Infrastructure Development Corporation (IDCO) after Union Ministry of Environment, Forest and Climate Change granted Stag-II or final approval in favour of road project.

Zepto shares crash 30% in unlisted market despite Sebi nod for IPO. What's cooking?

The unlisted shares of Zepto Limited have fallen nearly 30% over the past month despite the company securing regulatory approval for its IPO, highlighting growing caution among investors amid volatile market conditions.Zepto's shares, which were changing hands at around Rs 52 in the unlisted market a month ago, have dropped to about Rs 40, according to dealers tracking pre-IPO transactions.The decline comes even as the quick commerce startup recently received approval from Sebi to launch its much-awaited public issue. The company had taken the confidential route to file the DRHP but may soon file its papers publicly in June, according to Bloomberg.Analysts said the fall reflects weakness in the unlisted market and a broader reassessment of valuations rather than any company-specific development. The company is being valued at around Rs 38,000 crore in the dealer market.Several companies that had planned public offerings this year have either delayed listings or adopted a wait-and-watch approach because of volatility in equity markets, geopolitical tensions and uncertainty around investor demand.The benchmark Nifty has remained under pressure for much of 2026, while foreign institutional investors have continued to remain cautious on Indian equities amid concerns over crude oil prices, global growth and the earnings outlook.The weakness in the secondary market for pre-IPO shares has also affected several startup names, with investors becoming more selective on valuations after a strong rally in the segment over the past two years.Zepto is preparing for a public market debut that could raise around $1.3 billion, or roughly Rs 11,000-12,000 crore, making it one of the largest internet IPOs since the listing of Swiggy.If the issue proceeds as planned, Zepto could become the youngest venture-backed Indian startup to enter public markets, just four years after its founding.The proposed offering is expected to comprise a substantial fresh issue of around Rs 11,000 crore along with an offer-for-sale component by existing investors.The IPO assumes significance because it comes amid intensifying competition in India's fast-growing quick commerce sector.Zepto competes with Blinkit, owned by Eternal, as well as Swiggy Instamart, Flipkart Minutes and Amazon Now.The listing is also expected to strengthen the company's balance sheet at a time when the quick commerce industry continues to spend aggressively on expansion, dark stores and customer acquisition.As of late last year, Zepto had around Rs 7,000 crore in cash, significantly lower than the roughly Rs 17,000-18,000 crore cash reserves reported by listed rivals Eternal and Swiggy.The company raised $450 million in October last year at a valuation of $7 billion. Following the fundraise, it accelerated customer acquisition efforts through higher discounts and promotional campaigns as competition intensified across major cities.Zepto had also completed its domicile shift from Singapore to India, a move increasingly adopted by venture-backed startups preparing for domestic listings.The company has appointed a consortium of investment bankers including Morgan Stanley, HSBC, Goldman Sachs, Axis Capital, JM Financial, IIFL Securities and Motilal Oswal Financial Services to manage the public issue. The IPO is expected to hit the market in the July-September quarter of 2026.While the recent decline in the unlisted share price may reflect near-term market caution, investors will closely watch the final valuation and broader market conditions when Zepto eventually launches what is expected to be one of the year's most closely watched public offerings.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

2 mainboard IPOs set to hit D-Street after a month of lull

India's primary market is set for an active week in the mainboard segment, with two public issues scheduled to open for subscription even as investor sentiment remains selective amid volatile equity markets and heightened global uncertainty. The spotlight will be on the IPOs of CMR Green Technologies and Hexagon Nutrition, which together aim to raise nearly Rs 770 crore.The offerings come at a time when the IPO market has seen a lull for a few weeks in a tepid 2026. While several companies have secured regulatory approvals in recent weeks, many have put off their IPO plans due to market volatility.The first issue to hit the market next week will be CMR Green Technologies. The company's IPO will open on June 3 and close on June 5. The issue is priced in the range of Rs 182-192 per share and aims to raise Rs 630.9 crore. Equirus Capital is managing the offering.CMR Green Technologies operates in the metal recycling and circular economy segment, manufacturing recycled aluminium and zinc products for automotive and industrial applications. The company counts several leading automotive manufacturers among its customers and is positioned to benefit from increasing adoption of recycled metals and sustainability-focused manufacturing practices.The company is expected to attract investor interest given the growing focus on resource efficiency, electric vehicles and environmental regulations that are encouraging the use of recycled materials.The second mainboard issue scheduled for next week is Hexagon Nutrition.The IPO will open on June 5 and close on June 9. The company has fixed a price band of Rs 42-45 per share and plans to raise Rs 138.9 crore through an offer for sale of 3.09 crore shares. Since the issue is entirely an OFS, the company will not receive any proceeds from the public offering.Hexagon Nutrition is a research-driven nutrition company engaged in manufacturing micronutrient premixes, wellness and clinical nutrition products, therapeutic formulations and ready-to-use nutritional foods.Founded in 1993, the company operates manufacturing facilities in Maharashtra, Tamil Nadu and Uzbekistan and exports products to more than 75 countries. Its products are sold through both business-to-consumer and business-to-business channels and include brands such as Pentasure, Obesigo, Pediagold and Nutrone.The company has reported steady financial growth in recent years. Profit after tax rose to Rs 24.4 crore in FY25 from Rs 12.2 crore in FY24 and Rs 5.8 crore in FY23, while total income increased to Rs 331 crore.At the upper end of the price band, Hexagon Nutrition is valued at around 15 times post-issue earnings.Market participants will closely watch subscription trends in both issues as they could provide a signal on investor appetite for new listings after months of fluctuating market sentiment.The broader market environment remains mixed. Indian equities have faced pressure this year from elevated crude oil prices, geopolitical tensions in West Asia and foreign institutional investor outflows. However, strong domestic liquidity and continued retail participation have helped support primary market activity.SME segmentApart from the mainboard issues, the SME segment is also expected to remain active next week.Genxai Analytics plans to raise about Rs 55 crore through its NSE SME IPO, which opens on June 5 and closes on June 9. The issue is priced at Rs 110-116 per share. Vahh Chemicals will launch a fixed-price SME issue worth Rs 13.5 crore between June 4 and June 8 on the BSE SME platform.Merritronix will also tap the SME market with a Rs 70 crore issue opening on June 1 and closing on June 3.While SME offerings continue to attract investor interest, listing performance has remained mixed in recent months, making subscription quality and valuation discipline increasingly important factors for investors.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Oppn. accuses Kochi Mayor of ‘abuse of power’ over extension of biomining agreement

LDF alleges that the contract with the company engaged in biomining legacy waste was renewed after its expiry without the council’s approval

Wockhardt secures US FDA approval for Zaynich

US judge raps Kennedy Center's board for adding Trump's name to building, blocks closure for renovation

A federal judge blocked the Trump administration from closing the Kennedy Center for renovations and ruled that adding Donald Trump’s name to the cultural venue was illegal without congressional approval. The ruling came amid lawsuits challenging the renovation and renaming plans.

US judge orders removal of Trump's name from Kennedy Center, blocks closure plan

A US federal judge has ordered the Trump administration to remove President Trump's name from the Kennedy Center. The court ruled that renaming the Washington institution, a memorial to John F. Kennedy, requires congressional approval. The judge mandated the removal of all Trump signage and references within two weeks, following a board decision that faced significant backlash.

Molecule glue drugs shake up cancer care

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.

Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic

Wockhardt shares rallied sharply on Friday, surging 7.87% to hit Rs 1,910.50 after the pharmaceutical company received a major regulatory boost for its breakthrough antibiotic, Zaynich. Notably, the stock has climbed nearly 12% in just the last two trading sessions, reflecting strong investor optimism following the development.In an exchange filing, Wockhardt announced that the Central Drugs Standard Control Organisation (CDSCO) has approved the import and marketing of its indigenously discovered and developed first-in-class antibiotic, Zaynich (Zidebactam/Cefepime), in India.The approval covers the treatment of adult patients suffering from complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases involving concurrent Gram-negative bacteremia.The nod is backed by strong results from the pivotal ENHANCE-1 Phase 3 clinical trial, a multinational, randomised, double-blind study comparing Zaynich with Meropenem — one of the widely used antibiotics for severe infections.The results significantly favoured Zaynich. The study showed that 89% of patients treated with Zaynich achieved clinical cure and microbiological eradication, compared with 68.4% in the Meropenem arm, delivering a treatment advantage of 20.6%.Even more striking were the outcomes in high-risk bacteremia patients, where Zaynich posted an 89% response rate versus just 44% for Meropenem, highlighting its potential as a game-changing therapy in severe drug-resistant infections.The company stated that Zaynich could emerge as a critical weapon against carbapenem-resistant infections — an area where existing treatment options like colistin and polymyxins often face limitations due to toxicity and weaker efficacy. Importantly, the drug is designed to combat metallo-β-lactamase (MBL)-mediated resistance, one of the toughest and most widespread antibiotic resistance mechanisms in India.Wockhardt Shares: Price trend and technical outlookWockhardt shares have surged nearly 27% over the past month, while the stock has skyrocketed an astounding 946% in the last three years, turning investor wealth nearly 10-fold during the period. The company currently commands a market capitalisation of around Rs 28,777 crore.On the technical front, Trendlyne data indicates that Wockhardt’s 14-day Relative Strength Index (RSI) stands at 72.3. An RSI above 70 is generally considered overbought, suggesting the stock could witness some profit-booking or a short-term pullback after the recent sharp rally.However, the overall trend remains firmly bullish, with the stock trading above all 8 out of 8 key simple moving averages (SMAs), indicating sustained strength in momentum.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

JP Power shares surge 28% in 2 days, Adani Power hits fresh 52-week high amid optimism around stake acquisition

Shares of Jaiprakash Power Ventures (JP Power) jumped another 7% on Friday, extending gains to a whopping 28% over just two sessions, while Adani Power shares hit a fresh 52-week high amid optimism over the latter's stake acquisition in the former.Shares of JP Power rose to Rs 24.50 apiece on Friday morning. The stock has rallied nearly 31% so far this week. Trading volumes continue to remain high, as more than 24 crore shares worth Rs 572 crore were traded on NSE in just 15 minutes from opening.Adani Power shares, meanwhile, gained more than 2% to hit a fresh 52-week high of Rs 254 apiece on Friday. The stock has jumped more than 69% so far in 2026 and 128% in one year as soaring temperatures across India hiked hopes for higher power demand.Last week, Adani Power said it has signed definitive agreements with Jaiprakash Associates (JAL) to acquire a 24% stake in Jaiprakash Power Ventures Limited (JPVL) along with the 180 MW Churk thermal power plant in Uttar Pradesh under the NCLT-approved resolution plan for JAL.The Adani Group company said it entered into a share purchase agreement to acquire JAL’s 24% stake in JPVL for around Rs 2,994 crore. Additionally, it has signed a business transfer agreement to acquire the Churk thermal power plant and associated assets, including JAL’s 11.49% stake in Prayagraj Power Generation Company Limited, for Rs 1,200 crore.Adani Power's acquisitions will strengthen its generation portfolio and expand its footprint in the thermal power sector, the company said. It added that they will be completed through cash consideration and are expected to close on the “Effective Date” under the approved resolution plan, which is scheduled to occur within 90 days from the NCLT approval granted on March 17, 2026.The Adani Group last Thursday paid around Rs 6,000 crore to lenders of debt-ridden Jaiprakash Associates as the first tranche of its Rs 14,535 crore resolution plan, marking a key milestone in one of the longest-running insolvency cases. "The fund transfer happened on Thursday. This was a big day for lenders because they will receive a large amount after such a long delay," a person aware of the development told The Economic Times.The insolvency proceedings involving Jaiprakash Associates have been underway for a few years, after the company formally entered the Corporate Insolvency Resolution Process (CIRP) in June 2024. The Allahabad bench of the National Company Law Tribunal approved Adani Enterprises' resolution plan on March 17 this year.Also read: Legacy of Jaiprakash Associates will be carried forward under Adani, says Jaiprakash Gaur(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

US-Iran Peace Deal LIVE updates: Trump shares shows peace deal to Israel, before sign-off; Vance says US ‘not there yet'

US-Iran Peace Deal LIVE updates: US and Iran have reached a draft ceasefire agreement, but Trump's approval remains pending as missile violations, nuclear red lines and fresh sanctions threaten to derail the deal.

Supreme Court tells CCI to protect competition without weakening market confidence; clears Amazon

The court concluded that the CCI acted outside its statutory authority by withdrawing the approval given to the Amazon-Future Coupons combination in 2019

IDBI Bank sale back on table: Centre

New Delhi: The Centre is exploring ways to revive the stalled privatisation of IDBI Bank, people familiar with the matter told ET. The choices include examining whether earlier rejected bids, from Prem Watsa-led Fairfax Financial Holdings and Emirates NBD, for their failure to hurdle the reserve price threshold could still be considered, they said.The bids remain ‘alive’ and the government is examining legal provisions under the tendering framework that allows for bids to be accepted even if offers are below the reserve price, said the people cited above.The reserve price remains undisclosed. A call is expected to be taken soon as the government looks at ways to bolster its non-tax revenues. A senior government official said that all options are on the table, as the process for selling its stake in IDBI Bank was never "scrapped" even after the financial bids were found to be below the reserve price. "Multiple options are being examined including how to complete the transaction in the ongoing round,” an official said. The government fixed the reserve price after bids were submitted by interested parties but before they were opened.Also Read: Listed banks earned a record profit of ₹4 lakh crore in FY26The reserve price remains confidential and has not been disclosed to bidders. The Centre may also seek guidance from, the Securities and Exchange Board of India, given the valuation concerns considering a very limited free public float, currently at 5.29%. 131377481Low Public Float"All these aspects are being examined," said another official. In February 2026, Arunish Chawla, secretary, Department of Investment and Public Affairs, or DIPAM, had said in a post on X that financial bids had been received for the strategic disinvestment of the IDBI Bank."They will be evaluated as per the prescribed procedure," he stated. But the stake sale process came to a halt in March after the bids received were found to be below the reserve price. IDBI's share price then crashed from a 52- week high of Rs 118.45 to a 52-week low on March 30 at Rs 61.05 at the Bombay Stock Exchange, or BSE.Also Read: Mid-tier entities in Indian BFSI under-invested in security, most exposed to cyberattacksThe stock gained some momentum in April and is currently trading at Rs 73.49 on the BSE. The government aims to sell its 30.48% stake and Life Insurance Corporation of India's 30.24% stake in the bank. At the current market price, it will be able to raise around Rs 24,000 crore. The government has budgeted Rs 80,000 crore from asset monetisation in this fiscal.As per the process, the successful bidder will have to go through a final assessment by the Reserve Bank of India (RBI) to ensure that it meets the regulator’s ‘fit & proper’ standards. In addition, approvals will be needed from statutory and regulatory authorities, including the Competition Commission of India. The successful bidder will also have to comply with the requirement to make an open offer to minority shareholders of IDBI Bank.

US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefire

​The S&P 500 and the Nasdaq posted record closing highs on Thursday after news reports said the U.S. and Iran had reached a draft agreement to extend their ceasefire for 60 days, while investors also digested key inflation data.The news was first reported by Axios, which said that negotiations ‌on Iran's nuclear program ⁠would ⁠be held during the truce period, but that the plan still needed the approval of President Donald Trump."Traders are on a hair trigger with the back-and-forth ​on deal news, and have been leaning long to avoid getting trampled by a better-than-expected outcome. The harder part is that the inflationary forces ​may not abate as fast as markets want," said Jamie Cox, managing partner at Harris Financial Group. Economic data showed U.S. inflation increased at its fastest pace in three years in April, driven by higher energy prices amid the Iran war. Meanwhile, U.S. ​GDP for the first quarter was revised lower to a 1.6% annualized increase, ⁠with momentum expected ‌to slow this quarter.According to preliminary data, the S&P 500 gained 43.50 points, or 0.58%, to ​end at 7,563.71 ​points, while the Nasdaq Composite gained 239.79 points, or 0.91%, to 26,917.47. The Dow Jones Industrial Average ⁠rose 24.11 points, or 0.04%, to 50,666.29. The S&P 500 healthcare index posted strong ​gains. Eli Lilly advanced after CVS Health said it would restore the drugmaker's weight-loss injection, ​Zepbound, to its coverage and add its newly approved obesity pill Foundayo.Tech shares also moved higher. Microsoft gained after news website the Information reported that the company would release a new coding model next week.Marvell Technology rose after UBS raised its target price to $230 from $195.The company's shares have more than doubled so far this year.Snowflake shares soared after the data analytics firm lifted its annual product revenue forecast and announced a five-year AI infrastructure deal worth $6 billion with Amazon Web Services.Peers Datadog and MongoDB also ‌climbed.Renewed confidence in AI and earnings growth momentum have underscored the recent rally despite the Middle East tensions, which have increased inflationary expectations."Markets continue to look through these risks because the global economy and ​corporate earnings remain ​relatively resilient," said Jitania Kandhari, deputy CIO, ⁠solutions and multi-assets, at Morgan Stanley Investment Management."Geopolitical instability could ultimately accelerate spending in areas tied to AI, including cybersecurity, defense technology, energy infrastructure and supply-chain resiliency, reinforcing the long-term investment case."While the S&P 500 is trading at roughly 21 to ​22 times forward earnings versus a trailing 10-year average of 19.7 times, investors are less concerned because earnings expectations are rising faster than stock prices, Kandhari said. Among other movers, Dollar Tree climbed after the discount retailer lifted its full-year profit forecast, while Best Buy also rose after the electronics vendor forecast second-quarter sales above estimates. Drone companies rose after the Wall Street Journal reported that the Trump administration was in talks to fund drone firms. Shares of Unusual Machines surged.

US, Iran Agree On Deal Framework, Awaiting Trump Approval: Report

US, Iran Agree On Deal Framework, Awaiting Trump Approval: Report

Quote of the Day by Oscar Wilde: ‘The only possible society is oneself’ —Why self-acceptance matters

Oscar Wilde's quote emphasises the importance of self-acceptance over societal approval. He suggests that true individuality and inner peace stem from valuing oneself, rather than seeking validation from others, which is crucial in today's comparison-driven world.

US and Iran reach deal to extend ceasefire but need Trump's final approval: Report

The US and Iran have a 60-day agreement to extend the ceasefire and begin negotiations on Iran's nuclear program, pending final approval from President Donald Trump, Axios reported on Thursday.

US, Iran reach deal but need Trump’s final approval

Bharat Dynamics Q4 Results: Net profit tumbles 59% to Rs 113 crore; dividend announced

Defence major Bharat Dynamics (BDL) on Thursday reported a standalone net profit of Rs 113.18 crore for the January-March quarter of the financial year 2026, marking a 58.5% year-on-year (YoY) drop from the Rs 272.77 crore net profit reported in the corresponding quarter of the previous financial year.Revenue from operations more than halved, dropping nearly 73% YoY to Rs 480 crore during the quarter under review, as against Rs 1,777 crore reported in the year-ago period.Total expenses also sharply declined to Rs 445.47 crore in Q4 FY26 from Rs 1,498 crore in the year-ago period. Total income fell to Rs 599 crore in the January-March quarter of FY26, from Rs 1,876 crore in the same period last year.Along with the Q4 results, Bharat Dynamics said that its board of directors have recommended a final dividend of Rs 0.40 per equity share with a face value of Rs 5 each for the financial year which ended on March 31. This is however subject to shareholders’ approval at its upcoming Annual General Meeting (AGM).BDL FY26 ResultsFor the entire financial year which ended on March 31, 2026, Bharat Dynamics reported a standalone net profit of Rs 420 crore, marking a 23% YoY drop from the Rs 550 crore net profit reported in FY25. The firm’s revenue from operations meanwhile fell 27% YoY to Rs 2,442 crore in FY26.Total expenses also reduced to Rs 2,298 crore, while total income fell to Rs 2,866 crore during the financial year. Earnings per share (EPS) meanwhile fell to Rs 11.47 per share in FY26, from Rs 14.99 per share in FY25.BDL share priceBharat Dynamics announced its earnings on March 28, when markets were closed on account of Bakrid. The stock will be in focus tomorrow when markets reopen. The stock has fallen over 1% in one week, 7% in one month and are down 13% so far in 2026.The shares of the defence player have declined 33% in one year, but gained over 145% in three years and 621% in five years.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)